Exelixis, Inc. Announces COMETRIQ™ (cabozantinib) Is Now Available in the U.S.

OUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced the commercial availability of COMETRIQ® (cabozantinib) for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). The U.S. Food and Drug Administration (FDA) approved COMETRIQ on November 29, 2012. COMETRIQ is being distributed exclusively through Diplomat Specialty Pharmacy in the U.S.